Discussion
right-sided colon cancer, DLTs
PRIMARY TUMOR, DISEASE
This phase Ib/II study aimed to determine the MTD and/or RP2D of the MEKi binimetinib given in combination with the EGFRi panitumumab and to investigate the efficacy and safety of the combination treatment in patients with mCRC. While there were no DLTs at the full dose of both agents, the combination was difficult to tolerate. There was limited clinical activity, and consequently, study enrollment was closed, and disease progression/survival follow-up were discontinued. The 30-day safety follow-up was not changed.The MTD/RP2D of the combination of binimetinib + panitumumab was determined to be binimetinib 45 mg BID + panitumumab 6 mg/kg Q2W. The treatment demonstrated limited clinical activity in adult patients with either In this study, patients were enrolled irrespective of primary tumor site. Patients with right-sided colon cancer primary sites are less likely to respond to EGFRi.The reversibility of acquired resistance to EGFRi upon withdrawal of treatment, and the subsequent restoration of drug sensitivity, has been documented in mCRC.The clinical development of binimetinib in combination with other therapeutic agents for patients with mCRC is ongoing. In the open-label, phase III BEACON study, the combination of encorafenib + cetuximab + binimetinib resulted in a significantly higher OS and ORR than standard therapy in patients with The similar rates of disease control between patient subgroups observed in the current study, regardless of prior EGFRi exposure, may help to further delineate the impact of Limitations of this study include the early closure of study enrollment due to a lack of clinical activity and the small number of patients enrolled into phase II, particularly in the acquired In conclusion, combination treatment with binimetinib + panitumumab exhibited limited clinical activity in adult patients with 